Treatment and management of hypersensitivity reactions developed against anti-tuberculosis drug

Treatment and management of hypersensitivity reactions developed against anti-tuberculosis drug

Background: The World Health Organization Global Tuberculosis Report 2021 defines tuberculosis as the second infectious disease that causes sickness and death after COVID 19 and ranks it as the 13th among the global causes of death. However, the prevalence of the patients developing a hypersensitivi...

Full description

Bibliographic Details
Main Authors: Zeynep Yegin Katran, Ismet Bulut, Aylin Babalik, Metin Keren
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:International Journal of Mycobacteriology
Subjects:
drug hypersensitivity
pyrazinamide
tuberculosis
type 1 hypersensitivity
type 4 hypersensitivity
Online Access:http://www.ijmyco.org/article.asp?issn=2212-5531;year=2022;volume=11;issue=3;spage=309;epage=317;aulast=Katran

Internet

http://www.ijmyco.org/article.asp?issn=2212-5531;year=2022;volume=11;issue=3;spage=309;epage=317;aulast=Katran

Similar Items